\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes ERC EICThe calls for which deadlines will be extended for all applicants, irrespective of the country where the organisation is based, are the following:
The deadline for the EIC Accelerator cut-off for full (Step 2) proposals has been changed from 19 October to 8 November 2023 at 17:00 (CET).
At the same time, the 12-month limit to submit a full application following the successful evaluation of a short (Step 1) proposal is extended. Successful Step 1 applicants who exceed(ed) the maximum 12 months for submitting a full (Step 2) proposal between 7 June 2023 cut-off date and 8 November 2023 cut-off date, are allowed to submit a full (Step 2) proposal to the 8 November cut-off date. Funding and tender portal call topic pages
The new call deadlines for the EIC calls are visible on the European Commission Funding and tender portal already and for the ERC calls will be added soon.
More information on the background of this decision from the European Commission can be found in this European Commission DG Research and Innovation news article. The ERC and EIC each also published the news ERC news article and EIC news article
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
